EUVIMEDEUVIMED entdecken
Crossref

Evaluation of 161Tb-Labeled DOTA-Ibandronate for Targeted Radionuclide Therapy in Bone Metastases

Chunfang Zhang, Yingwei Wang, Jia Deng, Die You, Ya Liu, Lei Lei, Yan Zhao, Jian Yang, Li Wang iD, Wei Wang, Yue Chen iD

Molecular Pharmaceutics · 03.08.2026 · 23 (8) · 4069-4078

DOI: 10.1021/acs.molpharmaceut.5c01869 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 14.07.2026. Verfasst von Chunfang Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Nuclear Medicine and Theranostics Key Laboratory of Sichuan Province, The Affiliated Hospital of Southwest Medical Un…. Hauptthemen laut MEDLINE: Bone Neoplasms, Radiopharmaceuticals, Ibandronic Acid, Terbium. Die Arbeit nennt 30 Literaturangaben. Gefördert von: Science and Technology Department of Sichuan Province, Science and Technology Program of Gansu Province, medical isotope production technology and targeted radiopharmaceuticals research of Gansu Isotope Laboratory.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Building upon our previous work on [68Ga]Ga/[177Lu]Lu-DOTA-Ibandronate and its demonstrated clinical applicability, this study investigates the biological behavior and translational potential of the novel therapeutic radiopharmaceutical terbium-161 (161Tb)-labeled DOTA-IBA. The radiolabeling parameters of [161Tb]Tb-DOTA-IBA were first optimized, followed by a systematic assessment of its physicochemical characteristics. Biodistribution, micro-SPECT/CT imaging, and therapeutic efficacy were evaluated in a 4T1 mouse model of bone metastasis to determine pharmacokinetics and bone-targeting capacity. Safety was verified through dose-escalation experiments. Furthermore, a preliminary clinical evaluation was performed in one volunteer with bone metastases to validate safety and initial therapeutic efficacy. [161Tb]Tb-DOTA-IBA was obtained with radiochemical purity exceeding 98%, demonstrating excellent bone-targeting selectivity and retention, with a 24 h bone uptake of 30.61 ± 4.61% ID/g, which is substantially higher than in soft tissues. In a patient receiving 370 MBq, marked pain relief was achieved, reflected by decreased VAS scores, with therapeutic benefit lasting 8–12 weeks and no observed toxic reactions. The compound exhibited favorable pharmacokinetics and safety, with no ≥ grade 3 adverse events. Overall, [161Tb]Tb-DOTA-IBA displayed high tumor-to-background ratios and excellent pharmacokinetic behavior. Early human data confirmed its safety and therapeutic potential. The complementary use of [68Ga]Ga/[161Tb]Tb-DOTA-IBA enables a unified diagnostic-therapeutic platform for the management of bone metastases, providing an innovative, targeted treatment option capable of improving both quality of life and survival in patients with advanced skeletal disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone NeoplasmsRadiopharmaceuticalsIbandronic AcidTerbiumRadioisotopesDiphosphonatesAnimalsHumansMiceFemaleTissue DistributionMice, Inbred BALB CCell Line, TumorSingle Photon Emission Computed Tomography Computed TomographyMiddle Aged

Stichwörter der Autor:innen

SPECTbone metastasisibandronate sodiumradioligand therapyterbium-161

Substanzen

RadiopharmaceuticalsIbandronic AcidTerbiumRadioisotopesDiphosphonates

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Nuclear Medicine and Theranostics Key Laboratory of Sichuan Province, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan646000, PR China.
  • Argeted Radiopharmaceuticals Creation Key Laboratory of Sichuan Province, Luzhou, Sichuan646000, PR China.
  • Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan646000, PR China.

ORCID-Profile: Li Wang, Yue Chen

Förderung

  • Science and Technology Department of Sichuan Province
  • Science and Technology Program of Gansu Province
  • medical isotope production technology and targeted radiopharmaceuticals research of Gansu Isotope Laboratory

Zitieren

APA

Zhang, C., Wang, Y., Deng, J., You, D., Liu, Y., Lei, L., Zhao, Y., Yang, J., Wang, L., Wang, W., & Chen, Y. (2026). Evaluation of 161Tb-Labeled DOTA-Ibandronate for Targeted Radionuclide Therapy in Bone Metastases. Molecular Pharmaceutics, 23(8), 4069-4078. https://doi.org/10.1021/acs.molpharmaceut.5c01869

Vancouver

Zhang C, Wang Y, Deng J, You D, Liu Y, Lei L, et al. Evaluation of 161Tb-Labeled DOTA-Ibandronate for Targeted Radionuclide Therapy in Bone Metastases. Molecular Pharmaceutics. 2026;23(8):4069-4078. doi:10.1021/acs.molpharmaceut.5c01869

BibTeX
@article{Zhang2026,
  author = {Zhang, Chunfang and Wang, Yingwei and Deng, Jia and You, Die and Liu, Ya and Lei, Lei and Zhao, Yan and Yang, Jian and Wang, Li and Wang, Wei and Chen, Yue},
  title = {Evaluation of 161Tb-Labeled DOTA-Ibandronate for Targeted Radionuclide Therapy in Bone Metastases},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  volume = {23},
  number = {8},
  pages = {4069--4078},
  doi = {10.1021/acs.molpharmaceut.5c01869}
}
Kostenlos starten →